Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.07.007Source: DataRank Database

A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial is a research paper published in Transplantation and Cellular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.18)OA: greenTopics (32)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

T Nishihori ORCID,Marcelo C. Pasquini ORCID,Michael J. Martens ORCID,Juan Wu ORCID,Melissa Alsina ORCID

Live enrichment

PubMed:35840087 PMC:PMC10442072 OpenAlex:https://openalex.org/W4285097809

NCI NIH HHS

Grant: P30 CA008748

NHLBI NIH HHS

Grant: UG1 HL108987

NHLBI NIH HHS

Grant: U01 HL069294

NHLBI NIH HHS

Grant: UG1 HL069286

NHLBI NIH HHS

Grant: U24 HL138660

National Institutes of Health

National Cancer Institute

National Heart, Lung, and Blood Institute

FWCI

1.18

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

greenLicense: http://creativecommons.org/licenses/by-nc-nd/4.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10442072/pdf/nihms-1837512.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666636722014671?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636722014671?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10442072

Fields of Study

Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsHematopoietic Stem Cell Transplantation

MeSH Terms

Bone MarrowBoron CompoundsGlycineGraft vs Host DiseaseHumansMultiple MyelomaProspective StudiesQuality of LifeTransplantation, Homologous

Keywords

MedicineIxazomibInternal medicineMultiple myelomaFludarabineHazard ratioTransplantationPlaceboClinical endpointMelphalanSurgeryOncologyClinical trialBortezomibChemotherapyCyclophosphamidePathologyConfidence intervalMaintenanceAllogeneic Hematopoietic Cell Transplantation

Sustainable Development Goals

SDG 0: Good health and well-being